A Description of Inflammatory Cell Types in Moderate to Severe Pediatric Asthma: Eosinophilic and Non Eosinophilic Sputum Markers While on Anti-IgE Therapy (Xolair).

Trial Profile

A Description of Inflammatory Cell Types in Moderate to Severe Pediatric Asthma: Eosinophilic and Non Eosinophilic Sputum Markers While on Anti-IgE Therapy (Xolair).

Completed
Phase of Trial: Phase IV

Latest Information Update: 27 Nov 2014

At a glance

  • Drugs Omalizumab (Primary)
  • Indications Allergic asthma
  • Focus Pharmacodynamics
  • Most Recent Events

    • 26 May 2010 Actual end date (Jan 2009) added as reported by ClinicalTrials.gov.
    • 26 May 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 30 Sep 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top